Vyome vs Soligenix
HIND and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HIND and SNGX compare
Vyome is the larger company, worth 1.6 times as much as Soligenix ($11.1M against $7.0M).
Soligenix scores higher on the StockData Score (6 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HIND | SNGX |
|---|---|---|
| Size and price | ||
| Market cap | $11.1M | $7.0M |
| Share price | $1.58 | $0.321 |
| Change, 1 year | −70.3% | −76.4% |
| Change, 5 years | −100.0% | −99.8% |
| Beta (5Y) | 1.56 | 0.61 |
| Employees | 18 | 14 |
| StockData Score | ||
| Total score | 1 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 72.4× | – |
| P/B | – | 1.1× |
| Growth | ||
| Revenue growth (TTM) | −55.6% | – |
| Revenue growth, 5Y average | −51.0% | – |
| Profitability | ||
| Gross margin | 50.4% | – |
| Operating margin | −2854% | – |
| Net margin | −2456% | – |
| Return on equity | −149% | −127% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −229.3× | – |
| Current ratio | 3.68 (better) | 3.00 |
| Altman Z-score | −12.31 (better) | −38.47 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −53.1% | – |
| Shareholder yield | −53.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 2.0% | 4.3% |
| Held by insiders | 6.8% | 0.69% |
| Short interest, % of float | 0.28% | 0.31% |
Go deeper
- HIND stock overview
- HIND income statement
- HIND valuation and score
- SNGX stock overview
- SNGX income statement
- SNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.